Goldman Sachs on Monday upgraded pharma giant Merck & Co. to Buy from Hold, citing its strong pipeline and cancer drug Keytruda. Goldman analyst Terence Flynn lifted Merck’s (MRK) price target to
Goldman Sachs on Monday upgraded pharma giant Merck & Co. to Buy from Hold, citing its strong pipeline and cancer drug Keytruda. Goldman analyst Terence Flynn lifted Merck’s (MRK) price target to
Chegg, reported better-than-expected 2Q earnings on Monday, as the technology-based learning platform, benefited from stronger demand due to the coronavirus-led stay-at-home directives. Chegg’s (CHGG) adjusted EPS jumped 61% to $0.37
Consumer-products maker, Clorox, reported solid 4Q earnings on Monday driven by pandemic-led demand for cleaning and disinfecting products. Clorox’s (CLX) earnings of $2.41 per share jumped 28% year-over-year and came
Shares of Cirrus Logic fell 3.1% in extended market trading on Monday as the company expects 2Q sales to be lower than analysts’ estimates. While 2Q revenue guidance was disappointing,
Shares of Newell Brands (NWL) fell 7.5% on Friday even after reporting better-than-expected 2Q earnings. At the same time though, the company said it expects supply-chain disruptions and soft demand